FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to oxazolopyrimidine compounds of formula I in any of its stereoisomer forms or its physiologically acceptable salt, wherein A is specified in NH, O and S; X is specified in (C1-C6)-alkanediyl, (C2-C6)-alkenediyl, and (C1-C6)-alkanediyloxy, wherein oxygen atom of (C1-C6)-alkanediyloxy group is related to the group R2; R1 is specified in hydrogen and (C1-C4)-alkyl; R2 is specified in phenylene, which is optionally substituted in one or more carbon atoms in the ring by identical or different substitutes R22; R3 is specified in (C1-C6)-alkyl optionally substituted by 1-3 fluorine atoms, or R3 is a residue of a saturated or unsaturated 5-merous - 10-merous monocyclic or bicyclic ring, which contains 0, 1 or 2 heteroatoms in the ring specified in N, O and S, and represents cyclopentyl, indanyl, phenyl, naphthyl, thiazole, isothiazole, pyridyl, benzothiazole or quinoline, and wherein a residue of the ring is optionally substituted in one or two carbon atoms in the ring by identical or different substitutes R31; R22 is specified in (C1-C4)-alkyl optionally substituted by 1-3 fluorine atoms; R31 is specified in halogen, (C1-C4)-alkyl optionally substituted by 1-3 fluorine atoms, (C1-C4)-alkyloxy optionally substituted by 1-3 fluorine atoms, and (C1-C4)-alkyl-S(O)m- optionally substituted by 1-3 fluorine atoms; m is equal to 0. The invention also refers to a pharmaceutical composition containing the compounds of formula I, and to a method for producing the compounds of formula I.
EFFECT: producing the compounds of formula I applicable for EDG-1 receptor activation.
14 cl, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
CARBOXYLIC ACID DERIVATIVES CONTAINING 2,5,7-SUBSTITUTED OXAZOLE PYRIMIDINE RING | 2011 |
|
RU2560876C2 |
DERIVATIVE OF HETEROCYCLIC CARBON ACIDS, WHICH CONTAIN 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | 2011 |
|
RU2554869C2 |
HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | 2011 |
|
RU2559896C2 |
2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | 2011 |
|
RU2554874C2 |
DERIVATIVES OF CARBOXYLIC ACIDS WITH OXAZOLE[5,4-d]PYRIMIDINE CYCLE | 2012 |
|
RU2609008C2 |
DERIVATIVES OF CARBOXYLIC ACIDS WITH OXAZOLE[5,4-b]PYRIDINE RING | 2012 |
|
RU2609002C2 |
CARBOXYLIC ACID DERIVATIVES, HAVING OXAZOLE[4,5-D]PYRIMIDINE RING | 2012 |
|
RU2609003C2 |
2,5,7-SUBSTITUTED OXAZOLPYRIMIDINE DERIVATIVES | 2011 |
|
RU2557246C2 |
DERIVATIVES OF CARBOXYLIC ACIDS WITH OXAZOLE[4,5-c]PYRIDINE CYCLE | 2012 |
|
RU2609004C2 |
CYANOISOQUINOLINE COMPOUNDS (VERSIONS), PHARMACEUTICAL COMPOSITION BASED THEREON, HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE INHIBITING METHOD AND METHOD OF TREATING AND/OR PREVENTING HIF-ASSOCIATED CONDITION AND/OR ERYTHROPOIETIN-AND/OR ANAEMIA-ASSOCIATED CONDITION | 2007 |
|
RU2457204C2 |
Authors
Dates
2015-09-27—Published
2011-01-12—Filed